pharma · Paroxysmal Nocturnal Hemoglobinuria (PNH) · Paroxysmal Nocturnal Haemoglobinuria (PNH) · AKTX
Akari Therapeutics
Akari Therapeutics Plc
Akari Therapeutics is a pharma organization headquartered in London, GB. It trades on NYSE under ticker AKTX. Primary therapeutic focus areas include Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Haemog
Company details
- Status
- Public
- HQ
- London, GB
- Employees
- 16
- Programs
- 9
- Drugs
- 0
- Patents
- 0
Quick answer
Akari Therapeutics is a pharma organization headquartered in London, GB. It trades on NYSE under ticker AKTX. Primary therapeutic focus areas include Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Haemoglobinuria (PNH), Atopic Dermatitis, Bullous Pemphigoid, Thrombotic Microangiopathies. NovaPharmaNews links 9 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (5), phase 3 (4).
Company snapshot
Akari Therapeutics is an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome modulator designed to disrupt RNA splicing within cells. PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors
- 9 active pipeline program(s) linked via ClinicalTrials.gov.
- 9 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Akari Therapeutics. Not investment advice.
Top assets
Lead pipeline drugs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Akari Therapeutics.
1 active signal
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Akari Therapeutics.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Akari Therapeutics?
-
Is Akari Therapeutics publicly traded?
-
What drugs does Akari Therapeutics develop or market?
-
What are the latest developments for Akari Therapeutics?
-
What therapeutic areas does Akari Therapeutics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.